Value of calretinin immunostaining in diagnostic pathology: A review and update

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 6, 2014, Pages 401-415

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adrenal cortical neoplasm; Ameloblastoma; Calretinin; Cardiac myxoma; HIRSCHSPRUNG disease; Immunohistochemistry; Mesothelioma; Sex cord stromal tumor

Indexed keywords

CALRETININ; CALB2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADRENAL CORTEX TUMOR; AMELOBLASTOMA; CENTRAL NERVOUS SYSTEM TUMOR; ESTHESIONEUROBLASTOMA; FEMALE GENITAL TRACT TUMOR; HEART MYXOMA; HIRSCHSPRUNG DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MESOTHELIUM CELL; NEOPLASM; NEURILEMOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEX CORD TUMOR; SKIN TUMOR; SOFT TISSUE TUMOR; TESTIS TUMOR; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; CALBINDIN 2; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904164745     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31829b6fbd     Document Type: Review

References (204)

1. Heizmann CW, Hunziker W. Intracellular calcium-binding proteins: more sites than insights. Trends Biochem Sci. 1991;16:98-103.
2. Andressen C, Blumcke I, Celio MR. Calcium-binding proteins: selective markers of nerve cells. Cell Tissue Res. 1993;271:181-208.
3. Rogers JH. Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons. J Cell Biol. 1987;105:1343-1353.
4. Parmentier M. Structure of the human cDNAs and genes coding for calbindin D28K and calretinin. Adv Exp Med Biol. 1990; 269:27-34.
5. Winsky L, Nakata H, Martin BM, et al. Isolation, partial amino acid sequence, and immunohistochemical localization of a brainspecific calcium-binding protein. Proc Natl Acad Sci USA. 1989;86:10139-10143.
6. Rogers J, Khan M, Ellis J. Calretinin and other CaBPs in the nervous system. Adv Exp Med Biol. 1990;269:195-203.
7. Schwaller B, Celio MR, Hunziker W. Alternative splicing of calretinin mRNA leads to different forms of calretinin. Eur J Biochem. 1995;230:424-430.
8. Schurmans S, Schiffmann SN, Gurden H, et al. Impaired long-term potentiation induction in dentate gyrus of calretinin-deficient mice. Proc Natl Acad Sci USA. 1997;94:10415-10420.
9. Schwaller B, Buchwald P, Blumcke I, et al. Characterization of a polyclonal antiserum against the purified human recombinant calcium-binding protein, calretinin. Cell Calcium. 1993;14: 639-648.
10. Camp AJ, Wijesinghe R. Calretinin: modulator of neuronal excitability. Int J Biochem Cell Biol. 2009;41:2118-2121.
11. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037-1046.
12. Novier A, Nicolas D, Krstic R. Colocalization of calretinin and glucagon in rat pancreatic A cells. Acta Histochem. 1997;99: 217-222.
13. Dei Tos AP, Doglioni C. Calretinin: a novel tool for diagnostic immunohistochemistry. Adv Anat Pathol. 1998;5:61-66.
14. Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract. 1996;192:137-147.
15. Ordóñez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38:1-16.
16. Ordóñez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol. 2013;44:1-19.
17. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol. 1997;21:1409-1419.
18. Leers MPG, Aarts MMJ, Theunissen PHMH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology. 1998;32:209-216.
19. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol. 1998;11:929-933.
20. Cury PM, Butcher DN, Fisher C, et al. Value of the mesotheliumassociated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000;13:107-112.
21. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: as assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology. 2000;36:341-347.
22. Comin CE, Novelli L, Boddi V, et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol. 2001;32: 529-536.
23. Miettinen M, Limon J, Niezabitowski A, et al. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Am J Surg Pathol. 2001;25:610-617.
24. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051.
25. Granville LA, Younes M, Churg A, et al. Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. Appl Immunohistochem Mol Morphol. 2005;13:75-79.
26. Hinterberger M, Reineke T, Storz M, et al. D2-40 and calretinin- a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 2007;20: 248-255.
27. Kushitani K, Takeshima Y, Amatya VJ, et al. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int. 2007;57: 190-199.
28. Takeshima Y, Amatya VJ, Kushitani K, et al. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases. Am J Clin Pathol. 2008;130:771-779.
29. Amatya VJ, Takeshima Y, Kohno H, et al. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology. 2009;55:10-19.
30. Ordóñez NG. Mesotheliomas with small cell features: report of eight cases. Mod Pathol. 2012;25:689-698.
31. Ordóñez NG. Pleomorphic mesothelioma: report of 10 cases. Mod Pathol. 2012;25:1011-1022.
32. Ordóñez NG. Deciduoid mesothelioma: report of 21 cases with review of the literature. Mod Pathol. 2012;25:1481-1495.
33. Ordóñez NG. Mesothelioma with signet-ring cell features: report of 23 cases. Mod Pathol. 2013;26:370-384.
34. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol. 2001;25:43-50.
35. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003;27:150-158.
36. Pan C-C, Chen PC-H, Chou T-Y, et al. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. Hum Pathol. 2003;34:1155-1162.
37. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105-110.
38. Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than a-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol. 2002;26:1477-1483.
39. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol. 2005;36:195-201.
40. Barnetson RJ, Burnett RA, Downie I, et al. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum. Antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol. 2006;125:67-76.
41. Ordóñez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006;19:34-48.
42. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol. 2007;31:1139-1148.
43. Gao FF, Krasinskas AM, Chivukula M. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin? Appl Immunohistochem Mol Morphol. 2012;20:272-276.
44. Duhig EE, Kalpakos L, Yang IA, et al. Mesothelial markers in high-grade breast carcinoma. Histopathology. 2011;59:957-964.
45. Powell G, Roche H, Roche WR. Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma. Histopathology. 2011;59:950-956.
46. Martignoni G, Pea M, Chilosi M, et al. Parvalbumin is constantly expressed in chromophobe renal carcinoma. Mod Pathol. 2001;14: 760-767.
47. Osborn M, Pelling N, Walker MM, et al. The value of "mesothelium- associated" antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas. Histopathology. 2002;41:301-307.
48. Lugli A, Forster Y, Haas P, et al. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol. 2003;34:994-1000.
49. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol. 2004;35:697-710.
50. Lapinski JE, Chen L, Zhou M. Distinguishing clear cell renal cell carcinoma, retroperitoneal paraganglioma, and adrenal cortical lesions on limited biopsy material: utility of immunohistochemical markers. Appl Immunohistochem Mol Morphol. 2010;18:414-421.
51. Sangoi AR, Fujiwara M, West RB, et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol. 2011;35:678-686.
52. Ordóñez NG. Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma. Mod Pathol. 2013. doi: 10.1038/modpathol.2013.34.
53. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006; 19:417-428.
54. Attanoos RL, Dojcinov SD, Webb R, et al. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology. 2000;37:224-231.
55. Kushitani K, Takeshima Y, Amatya VJ, et al. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int. 2008;58:75-83.
56. Takeshima Y, Amatya VJ, Kushitani K, et al. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Histopathology. 2009;54:667-676.
57. Foster MR, Johnson JE, Olson SJ, et al. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med. 2001;125:1316-1320.
58. Roberts F, Harper CM, Downie I, et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies. Am J Clin Pathol. 2001;116:253-262.
59. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55:662-668.
60. Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003;42:270-279.
61. Knuuttila A, Jee KJ, Taskinen E, et al. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases. Virchows Arch. 2006;448:135-141.
62. Padgett DM, Cathro HP, Wick MR, et al. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol. 2008;32:123-127.
63. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23:470-479.
64. Matsuyama A, Hisaoka M, Iwasaki M, et al. TLE1 expression in malignant mesothelioma. Virchows Arch. 2010;457:577-583.
65. Chirieac LR, Pinkus GS, Pinkus JL, et al. The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura. Am J Cancer Res. 2011;1:14-24.
66. Barak S, Wang Z, Miettinen M. Immunoreactivity for calretinin and keratins in desmoid fibromatosis and other myofibroblastic tumors: a diagnostic pitfall. Am J Surg Pathol. 2012;36: 1404-1409.
67. Fine SW, McClain SA, Li M. Immunohistochemical staining for calretinin is useful for differentiating schwannomas from neurofibromas. Am J Clin Pathol. 2004;122:552-559.
68. Cates JM, Coffing BN, Harris BT, et al. Calretinin expression in tumors of adipose tissue. Hum Pathol. 2006;37:312-321.
69. Schwartz EJ, Longacre TA. Adenomatoid tumors of the female and male genital tracts express WT1. Int J Gynecol Pathol. 2004;23:123-128.
70. Sangoi AR, McKenney JK, Schwartz EJ, et al. Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases. Mod Pathol. 2009; 22:1228-1235.
71. Wachter DL, Wünsch PH, Hartmann A, et al. Adenomatoid tumors of the female and male genital tract. A comparative clinicopathologic and immunohistochemical analysis of 47 cases emphasizing their site-specific morphologic diversity. Virchows Arch. 2011;458:593-602.
72. Kaplan MA, Tazelaar HD, Hayashi T, et al. Adenomatoid tumors of the pleura. Am J Surg Pathol. 1996;20:1219-1223.
73. Minato H, Nojima T, Kurose N, et al. Adenomatoid tumor of the pleura. Pathol Int. 2009;59:567-571.
74. Yeh CJ, Chuang WY, Chou HH, et al. Multiple extragenital adenomatoid tumors in the mesocolon and omentum. APMIS. 2008;116:1016-1019.
75. Craig JR, Hart WR. Extragenital adenomatoid tumor: evidence for the mesothelial theory of origin. Cancer. 1979;43:1678-1681.
76. Natarajan S, Luthringer DJ, Fishbein MC. Adenomatoid tumor of the heart: report of a case. Am J Surg Pathol. 1997;21:1378-1380.
77. Glatz K, Wegmann W. Papillary adenomatoid tumour of the adrenal gland. Histopathology. 2000;37:376-377.
78. Isotalo PA, Keeney GL, Sebo TJ, et al. Adenomatoid tumor of the adrenal gland: a clinicopathologic study of five cases and review of the literature. Am J Surg Pathol. 2003;27:969-977.
79. Hayes SJ, Clark P, Mathias R, et al. Multiple adenomatoid tumours in the liver and peritoneum. J Clin Pathol. 2007;60: 722-724.
80. Nagata S, Aishima S, Fukuzawa K, et al. Adenomatoid tumour of the liver. J Clin Pathol. 2008;61:777-780.
81. Overstreet K, Wixom C, Shabaik A, et al. Adenomatoid tumor of the pancreas: a case report with comparison of histology and aspiration cytology. Mod Pathol. 2003;16:613-617.
82. Plaza JA, Dominguez F, Suster S. Cystic adenomatoid tumor of the mediastinum. Am J Surg Pathol. 2004;28:132-138.
83. Brockstedt U, Gulyas M, Dobra K, et al. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol. 2000;114: 203-209.
84. Comin CE, Dini S, Novelli L, et al. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type. Am J Surg Pathol. 2006;30:463-469.
85. Bertschy S, Genton CY, Gotzos V. Selective immunocytochemical localisation of calretinin in the human ovary. Histochem Cell Biol. 1998;109:59-66.
86. Cao QJ, Jones JG, Li M. Expression of calretinin in human ovary, testis, and ovarian sex cord-stromal tumors. Int J Gynecol Pathol. 2001;20:346-352.
87. McCluggage WG, Maxwell P. Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours. Histopathology. 2001;38:403-408.
88. Deavers MT, Malpica A, Liu J, et al. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol. 2003;16:584-590.
89. Zhao C, Vinh TN, McManus K, et al. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol. 2009;33:354-366.
90. Al-Agha OM, Huwait HF, Chow C, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 2011;35:484-494.
91. Dong L, Wang H, Su Z, et al. Steroidogenic acute regulatory protein is a useful marker for Leydig cells and sex-cord stromal tumors. Appl Immunohistochem Mol Morphol. 2011;19:226-232.
92. Oliva E, Alvarez T, Young RH. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol. 2005;29:143-156.
93. Jones MW, Harri R, Dabbs DJ, et al. Immunohistochemical profile of steroid cell tumor of the ovary: a study of 14 cases and a review of the literature. Int J Gynecol Pathol. 2010;29:315-320.
94. Stewart CJ, Nandini CL, Richmond JA. Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. J Clin Pathol. 2000;53:206-211.
95. Choi YL, Kim HS, Ahn G. Immunoexpression of inhibin alpha subunit, inhibin/activin betaA subunit and CD99 in ovarian tumors. Arch Pathol Lab Med. 2000;124:563-569.
96. Zhao C, Barner R, Vinh TN, et al. SF-1 is a diagnostically useful immunohistochemical marker and comparable to other sex cordstromal tumor markers for the differential diagnosis of ovarian sertoli cell tumor. Int J Gynecol Pathol. 2008;27:507-514.
97. Shah VI, Freites ON, Maxwell P, et al. Inhibin is more specific than calretinin as an immunohistochemical marker for differentiating sarcomatoid granulosa cell tumour of the ovary from other spindle cell neoplasms. J Clin Pathol. 2003;56:221-224.
98. Zizi-Sermpetzoglou A, Petrakopoulou N, Tepelenis N, et al. Pure Sertoli cell tumor. a case report and review of the literature. Eur J Gynaecol Oncol. 2010;31:117-119.
99. Ordóñez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol. 2005;36:1163-1167.
100. Ordóñez NG. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol. 2013;26:553-562.
101. Neto AG, Deavers MT, Silva EG, et al. Immunohistochemical profile of ovarian small cell carcinoma, hypercalcemic type. Mod Pathol. 2003;16:202A.
102. McCluggage WG, Oliva E, Connolly LE, et al. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. Int J Gynecol Pathol. 2004;23:330-336.
103. Bai S, Wei S, Ziober A, et al. SALL4 and SF-1 are sensitive and specific markers for distinguishing granulosa cell tumors from yolk sac tumors. Int J Surg Pathol. 2013;21:121-125.
104. Devouassoux-Shisheboran M, Silver SA, Tavassoli FA. Wolffian adnexal tumor, so-called female adnexal tumor of probable Wolffian origin (FATWO): immunohistochemical evidence in support of a Wolffian origin. Hum Pathol. 1999;30:856-863.
105. Fukunaga M, Bisceglia M, Dimitri L. Endometrioid carcinoma of the fallopian tube resembling a female adnexal tumor of probable wolffian origin. Adv Anat Pathol. 2004;11:269-272.
106. Li CC, Qian ZR, Hirokawa M, et al. Expression of adhesion molecules and Ki-67 in female adnexal tumor of probable Wolffian origin (FATWO): report of two cases and review of the literature. APMIS. 2004;112:390-398.
107. Czernobilsky B, Lifschitz-Mercer B, Trejo L, et al. Granulosa cell tumor of the broad ligament: report of a case with emphasis on the differential diagnosis with female adnexal tumor of probable Wolffian origin. Int J Surg Pathol. 2011;19:783-786.
108. Syriac S, Durie N, Kesterson J, et al. Female adnexal tumor of probable Wolffian origin (FATWO) with recurrence 3 years postsurgery. Int J Gynecol Pathol. 2011;30:231-235.
109. Al Moghrabi H, Elkeilani A, Thomas JM, et al. Calretinin: an immunohistochemical marker for the normal functional endometrial stroma and alterations of the immunoreactivity in dysfunctional uterine bleeding. Pathol Res Pract. 2007;203:79-83.
110. Mai KT, Teo I, Al Moghrabi H, et al. Calretinin and CD34 immunoreactivity of the endometrial stroma in normal endometrium and change of the immunoreactivity in dysfunctional uterine bleeding with evidence of "disordered endometrial stroma". Pathology. 2008;40:493-499.
111. Silver SA, Devouassoux-Shisheboran M, Mezzetti TP, et al. Mesonephric adenocarcinomas of the uterine cervix: a study of 11 cases with immunohistochemical findings. Am J Surg Pathol. 2001;25:379-387.
112. McCluggage WG, Oliva E, Herrington CS, et al. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology. 2003;43:144-150.
113. Irving JA, Carinelli S, Prat J. Uterine tumors resembling ovarian sex cord tumors are polyphenotypic neoplasms with true sex cord differentiation. Mod Pathol. 2006;19:17-24.
114. Hurrell DP, McCluggage WG. Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers. J Clin Pathol. 2007;60:1148-1154.
115. Nogales FF, Stolnicu S, Harilal KR, et al. Retiform uterine tumours resembling ovarian sex cord tumours. A comparative immunohistochemical study with retiform structures of the female genital tract. Histopathology. 2009;54:471-477.
116. Abdullazade S, Kosemehmetoglu K, Adanir I, et al. Uterine tumors resembling ovarian sex cord-stromal tumors: synchronous uterine tumors resembling ovarian sex cord-stromal tumors and ovarian sex cord tumor. Ann Diagn Pathol. 2010;14: 432-437.
117. de Leval L, Lim GS, Waltregny D, et al. Diverse phenotypic profile of uterine tumors resembling ovarian sex cord tumors: an immunohistochemical study of 12 cases. Am J Surg Pathol. 2010;34:1749-1761.
118. Gupta M, de Leval L, Selig M, et al. Uterine tumors resembling ovarian sex cord tumors: an ultrastructural analysis of 13 cases. Ultrastruct Pathol. 2010;34:16-24.
119. Strauss KI, Isaacs KR, Ha QN, et al. Calretinin is expressed in the Leydig cells of rat testis. Biochim Biophys Acta. 1994;1219:435-440.
120. Paner GP, Kristiansen G, McKenney JK, et al. Rete testisassociated nodular steroid cell nests: description of putative pluripotential testicular hilus steroid cells. Am J Surg Pathol. 2011;35:505-511.
121. Augusto D, Leteurtre E, De La Taille A, et al. Calretinin: a valuable marker of normal and neoplastic Leydig cells of the testis. Appl Immunohistochem Mol Morphol. 2002;10:159-162.
122. Ulbright TM, Srigley JR, Hatzianastassiou DK, et al. Leydig cell tumors of the testis with unusual features: adipose differentiation, calcification with ossification, and spindle-shaped tumor cells. Am J Surg Pathol. 2002;26:1424-1433.
123. Valeri RM, Kotakidou R, Michalakis K, et al. Malignant Leydigcell tumor of the testis diagnosed by fine-needle aspiration using ThinPrep technique. Diagn Cytopathol. 2011;39:368-372.
124. Petersson F, Bulimbasic S, Sima R, et al. Large cell calcifying Sertoli cell tumor: a clinicopathologic study of 1 malignant and 3 benign tumors using histomorphology, immunohistochemistry, ultrastructure, comparative genomic hybridization, and polymerase chain reaction analysis of the PRKAR1A gene. Hum Pathol. 2010;41:552-559.
125. Zhang M, Kao C-S, Ulbright TM, et al. Testicular fibrothecoma: a report of 16 cases [abstract]. Mod Pathol. 2013;26(suppl 2):261A.
126. Du S, Powell J, Hii A, et al. Myoid gonadal stromal tumor: a distinct testicular tumor with peritubular myoid cell differentiation. Hum Pathol. 2012;43:144-149.
127. Zhang H, Bu H, Chen H, et al. Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors. Appl Immunohistochem Mol Morphol. 2008;16:32-39.
128. Sangoi AR, McKenney JK. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol. 2010;34:423-432.
129. Jorda M, De Madeiros B, Nadji M. Calretinin and inhibin are useful in separating adrenocortical neoplasms from pheochromocytomas. Appl Immunohistochem Mol Morphol. 2002;10:67-70.
130. Zhang PJ, Genega EM, Tomaszewski JE, et al. The role of calretinin, inhibin, melan-a, BCL-2, and c-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. Mod Pathol. 2003;16:591-597.
131. Schröder S, Padberg BC, Achilles E, et al. Immunocytochemistry in adrenocortical tumours: a clinicomorphological study of 72 neoplasms. Virchows Arch A Pathol Anat Histopathol. 1992;420: 65-70.
132. Komminoth P, Roth J, Schröder S, et al. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas. Implications for the differential diagnosis of adrenal gland tumors. Lab Invest. 1995;72:424-431.
133. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998;22:57-63.
134. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: An anti-melana monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595-602.
135. Fetsch PA, Cormier J, Hijazi YM. Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas. J Immunother. 1997;20:60-64.
136. Brookes SJ, Steele PA, Costa M. Calretinin immunoreactivity in cholinergic motor neurones, interneurones and vasomotor neurones in the guinea-pig small intestine. Cell Tissue Res. 1991;263: 471-481.
137. Barinka F, Druga R. Calretinin expression in the mammalian neocortex: a review. Physiol Res. 2010;59:665-677.
138. Kustermann A, Neuhuber W, Brehmer A. Calretinin and somatostatin immunoreactivities label different human submucosal neuron populations. Anat Rec (Hoboken). 2011;294:858-869.
139. Shintaku M, Honda T, Sakai T. Expression of podoplanin and calretinin in meningioma: an immunohistochemical study. Brain Tumor Pathol. 2010;27:23-27.
140. Mills SE, Frierson HF Jr. Olfactory neuroblastoma. A clinicopathologic study of 21 cases. Am J Surg Pathol. 1985;9:317-327.
141. Ordóñez NG, Mackay B. Neuroendocrine tumors of the nasal cavity. Pathol Annu. 1993;28(pt 2):77-111.
142. Wooff JC, Weinreb I, Perez-Ordonez B, et al. Calretinin staining facilitates differentiation of olfactory neuroblastoma from other small round blue cell tumors in the sinonasal tract. Am J Surg Pathol. 2011;35:1786-1793.
143. Katori Y, Jin ZW, Kawase T, et al. Developmental changes in the distribution of calretinin-immunoreactive cells in human fetal nasal epithelium. Okajimas Folia Anat Jpn. 2010;87:5-10.
144. Doglioni C, Dei Tos AP, Furlanetto A, et al. Calretinin: a novel immunocytochemical marker of neuronal differentiation in tumors of the brain [abstract]. Mod Pathol. 1996;9:140A.
145. Pelc K, Vincent S, Ruchoux MM, et al. Calbindin-d(28k): a marker of recurrence for medulloblastomas. Cancer. 2002;95:410-419.
146. Takei H, Schmiege L, Buckleair L, et al. Intracerebral schwannoma clinically and radiologically mimicking meningioma. Pathol Int. 2005;55:514-519.
147. Mangini J, Silverman JF, Dabbs DJ, et al. Diagnostic value of calretinin in mast cell lesions of the skin. Int J Surg Pathol. 2000;8:119-122.
148. Chilosi M, Facchettti F, Dei Tos AP, et al. bcl-2 expression in pleural and extrapleural solitary fibrous tumours. J Pathol. 1997;181:362-367.
149. Fine SW, Li M. Expression of calretinin and the alpha-subunit of inhibin in granular cell tumors. Am J Clin Pathol. 2003;119:259-264.
150. Cappello F, Barnes L. Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis. Pathology. 2001;33:142-148.
151. Churg A, Cagle P, Colby TV, et al. The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas. Am J Surg Pathol. 2011;35:1823-1829.
152. Hartel PH, Fanburg-Smith JC, Frazier AA, et al. Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol. 2007;20:760-759.
153. Engohan-Aloghe C, Aubain Sommerhausen Nde S, Noël JC. Ovarian involvement by desmoplastic small round cell tumor with leydig cell hyperplasia showing an unusual immunophenotype (cytokeratin negative, calretinin and inhibin positive) mimicking poorly differentiated sertoli leydig cell tumor. Int J Gynecol Pathol. 2009;28:579-583.
154. González-Guerra E, Kutzner H, Rutten A, et al. Immunohistochemical study of calretinin in normal skin and cutaneous adnexal proliferations. Am J Dermatopathol. 2012;34:491-505.
155. Sariya D, Ruth K, Adams-McDonnell R, et al. Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch Dermatol. 2007;143:613-620.
156. Mahalingam M, Nguyen LP, Richards JE, et al. The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. Mod Pathol. 2010;23:713-719.
157. Fine G, Morales A, Horn RC Jr. Cardiac myxoma. A morphologic and histogenetic appraisal. Cancer. 1968;22:1156-1162.
158. McComb RD. Heterogeneous expression of factor VIII/von Willebrand factor by cardiac myxoma cells. Am J Surg Pathol. 1984;8:539-544.
159. Landon G, Ordóñez NG, Guarda LA. Cardiac myxomas. An immunohistochemical study using endothelial, histiocytic, and smooth-muscle cell markers. Arch Pathol Lab Med. 1986;110: 116-120.
160. Johansson L. Histogenesis of cardiac myxomas. An immunohistochemical study of 19 cases, including one with glandular structures, and review of the literature. Arch Pathol Lab Med. 1989;113:735-741.
161. Deshpande A, Venugopal P, Kumar AS, et al. Phenotypic characterization of cellular components of cardiac myxoma: a light microscopy and immunohistochemistry study. Hum Pathol. 1996;27:1056-1059.
162. Farrell DJ, Bulmer E, Angus B, et al. Immunohistochemical expression of endothelial markers in left atrial myxomas: a study of six cases. Histopathology. 1996;28:147-152.
163. Miller DV, Tazelaar HD, Handy JR, et al. Thymoma arising within cardiac myxoma. Am J Surg Pathol. 2005;29:1208-1213.
164. Orlandi A, Ciucci A, Ferlosio A, et al. Cardiac myxoma cells exhibit embryonic endocardial stem cell features. J Pathol. 2006;209:231-239.
165. Boxer ME. Cardiac myxoma: an immunoperoxidase study of histogenesis. Histopathology. 1984;8:861-872.
166. Govoni E, Severi B, Cenacchi G, et al. Ultrastructural and immunohistochemical contribution to the histogenesis of human cardiac myxoma. Ultrastruct Pathol. 1988;12:221-233.
167. Tanimura A, Kitazono M, Nagayama K, et al. Cardiac myxoma: morphologic, histochemical, and tissue culture studies. Hum Pathol. 1988;19:316-322.
168. Goldman BI, Frydman C, Harpaz N, et al. Glandular cardiac myxomas. Histologic, immunohistochemical, and ultrastructural evidence of epithelial differentiation. Cancer. 1987;59:1767-1775.
169. Schmitt-Gräff A, Borchard F. Cardiac myxoma with a cytokeratinimmunoreactive glandular component. Pathol Res Pract. 1992;188: 217-221.
170. Pucci A, Bartoloni G, Tessitore E, et al. Cytokeratin profile and neuroendocrine cells in the glandular component of cardiac myxoma. Virchows Arch. 2003;443:618-624.
171. Terracciano LM, Mhawech P, Suess K, et al. Calretinin as a marker for cardiac myxoma. Diagnostic and histogenetic considerations. Am J Clin Pathol. 2000;114:754-759.
172. Acebo E, Val-Bernal JF, Gómez-Roman JJ. Thrombomodulin calretinin and c-kit (CD117) expression in cardiac myxoma. Histol Histopathol. 2001;16:1031-1036.
173. Val-Bernal JF, Acebo E, Gómez-Román JJ, et al. Anticipated diagnosis of left atrial myxoma following histological investigation of limb embolectomy specimens: a report of two cases. Pathol Int. 2003;53:489-494.
174. Mistry D, Altini M, Coleman HG, et al. The spatial and temporal expression of calretinin in developing rat molars (Rattus norvegicus). Arch Oral Biol. 2001;46:973-981.
175. Altini M, Coleman H, Doglioni C, et al. Calretinin expression in ameloblastomas. Histopathology. 2000;37:27-32.
176. Coleman H, Altini M, Ali H, et al. Use of calretinin in the differential diagnosis of unicystic ameloblastomas. Histopathology. 2001;38:312-317.
177. Alaeddini M, Etemad-Moghadam S, Baghaii F. Comparative expression of calretinin in selected odontogenic tumours: a possible relationship to histogenesis. Histopathology. 2008;52:299-304.
178. DeVilliers P, Liu H, Suggs C, et al. Calretinin expression in the differential diagnosis of human ameloblastoma and keratocystic odontogenic tumor. Am J Surg Pathol. 2008;32:256-260.
179. Nasr MR, Mukhopadhyay S, Zhang S, et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006;19:1631-1637.
180. Kapur RP. Can we stop looking? Immunohistochemistry and the diagnosis of Hirschsprung disease. Am J Clin Pathol. 2006;126:9-12.
181. Meier-Ruge W, Lutterbeck PM, Herzog B, et al. Acetylcholinesterase activity in suction biopsies of the rectum in the diagnosis of Hirschsprung's disease. J Pediatr Surg. 1972;7:11-17.
182. Patrick WJ, Besley GT, SmithII. Histochemical diagnosis of Hirschsprung's disease and a comparison of the histochemical and biochemical activity of acetylcholinesterase in rectal mucosal biopsies. J Clin Pathol. 1980;33:336-343.
183. Moore SW, Johnson G. Acetylcholinesterase in Hirschsprung's disease. Pediatr Surg Int. 2005;21:255-263.
184. Santos MM, Tannuri U, Coelho MC. Study of acetylcholinesterase activity in rectal suction biopsy for diagnosis of intestinal dysganglionoses: 17-year experience of a single center. Pediatr Surg Int. 2008;24:715-719.
185. Robey SS, Kuhajda FP, Yardley JH. Immunoperoxidase stains of ganglion cells and abnormal mucosal nerve proliferations in Hirschsprung's disease. Hum Pathol. 1988;19:432-437.
186. Nogueira AM, Barbosa AJ, Carvalho AA, et al. Usefulness of immunocytochemical demonstration of neuron-specific enolase in the diagnosis of Hirschsprung's disease. J Pediatr Gastroenterol Nutr. 1990;11:496-502.
187. Szabolcs MJ, Visser J, Shelanski ML, et al. Peripherin: a novel marker for the immunohistochemical study of malformations of the enteric nervous system. Pediatr Pathol Lab Med. 1996;16:51-70.
188. Abu-Alfa AK, Kuan SF, West AB, et al. Cathepsin D in intestinal ganglion cells. A potential aid to diagnosis in suspected Hirschsprung's disease. Am J Surg Pathol. 1997;21:201-205.
189. Petchasuwan C, Pintong J. Immunohistochemistry for intestinal ganglion cells and nerve fibers: aid in the diagnosis of Hirschsprung's disease. J Med Assoc Thai. 2000;83:1402-1409.
190. Wester T, Olsson Y, Olsen L. Expression of bcl-2 in enteric neurons in normal human bowel and Hirschsprung disease. Arch Pathol Lab Med. 1999;123:1264-1268.
191. Staines WA, Bettolli M, De Carli C, et al. Fast evaluation of intraoperative biopsies for ganglia in Hirschsprung's disease. J Pediatr Surg. 2007;42:2067-2070.
192. Matsuda H, Hirato J, Kuroiwa M, et al. Histopathological and immunohistochemical study of the enteric innervations among various types of aganglionoses including isolated and syndromic Hirschsprung disease. Neuropathology. 2006;26:8-23.
193. Holland SK, Hessler RB, Reid-Nicholson MD, et al. Utilization of peripherin and S-100 immunohistochemistry in the diagnosis of Hirschsprung disease. Mod Pathol. 2010;23:1173-1179.
194. Holland SK, Ramalingam P, Podolsky RH, et al. Calretinin immunostaining as an adjunct in the diagnosis of Hirschsprung disease. Ann Diagn Pathol. 2011;15:323-328.
195. Yang S, Donner LR. Detection of ganglion cells in the colonic plexuses by immunostaining for neuron-specific marker NeuN: an aid for the diagnosis of Hirschsprung disease. Appl Immunohistochem Mol Morphol. 2002;10:218-220.
196. Brewer KC, Mwizerva O, Goldstein AM. BMPRIA is a promising marker for evaluating ganglion cells in the enteric nervous system-a pilot study. Hum Pathol. 2005;36:1120-1126.
197. Karim S, Hession C, Marconi S, et al. The identification of ganglion cells in Hirschsprung disease by the immunohistochemical detection of ret oncoprotein. Am J Clin Pathol. 2006;126:49-54.
198. Burtelow MA, Longacre TA. Utility of microtubule associated protein-2 (MAP-2) immunohistochemistry for identification of ganglion cells in paraffin-embedded rectal suction biopsies. Am J Surg Pathol. 2009;33:1025-1030.
199. Barshack I, Fridman E, Goldberg I, et al. The loss of calretinin expression indicates aganglionosis in Hirschsprung's disease. J Clin Pathol. 2004;57:712-716.
200. Rodrigues M, Lourencao PL, Terra SA, et al. Calretinin immunohistochemistry versus acetylcholinesterase histochemistry in rectal biopsies for the diagnosis of Hirschsprung's disease [abstract]. Mod Pathol. 2013;26(suppl 2):175A.
201. Monforte-Muñoz H, Gonzalez-Gomez I, Rowland JM, et al. Increased submucosal nerve trunk caliber in aganglionosis: a "positive" and objective finding in suction biopsies and segmental resections in Hirschsprung's disease. Arch Pathol Lab Med. 1998; 122:721-725.
202. Kakita Y, Oshiro K, O'Briain DS, et al. Selective demonstration of mural nerves in ganglionic and aganglionic colon by immunohistochemistry for glucose transporter-1: prominent extrinsic nerve pattern staining in Hirschsprung disease. Arch Pathol Lab Med. 2000;124:1314-1319.
203. Guinard-Samuel V, Bonnard A, De Lagausie P, et al. Calretinin immunohistochemistry: a simple and efficient tool to diagnose Hirschsprung disease. Mod Pathol. 2009;22:1379-1384.
204. Kaçar A, Arik ök AT, Azili MN, et al. Calretinin immunohistochemistry in Hirschsprung's disease: an adjunct to formalin-based diagnosis. Turk J Gastroenterol. 2012;23:226-233.